Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Ideally, candidate drugs for NASH and associated liver fibrosis should be pleiotropic in mechanism and work upstream on multiple drivers of NASH, including lipotoxic lipid species, oxidative stress, and key modulators of inflammation, liver cell injury and fibrosis. Icosabutate has demonstrated an ability to target these pathways in preclinical NASH models with interim data from the ICONA trial supporting, at least non-invasively, the clinical translation of the highly promising pre-clinical data.